Phase 1 Study of the Poly (ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2016
At a glance
- Drugs E 7016 (Primary) ; Temozolomide (Primary)
- Indications Glioma; Malignant melanoma; Solid tumours
- Focus Adverse reactions
- 06 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 May 2010 New trial record